Sangamo in $3 billion gene-editing deal with Gilead

(Reuters) – U.S. drugmaker Gilead Sciences Inc will use Sangamo Therapeutics Inc’s gene-editing technology to develop cancer treatments in a deal potentially worth about $3 billion to Sangamo, the companies said on Thursday.


Source: Reuters Medical News

Leave a Reply

Your email address will not be published. Required fields are marked *